No Data
Express News | Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced Gist
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
Earnings Preview: KURA to Report Financial Results Post-market on May 01
Kura Oncology to Report First Quarter 2025 Financial Results
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $24
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40